Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00768183 · ClinicalTrials.gov registry record · Phase 1
Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to Water
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00768183 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 32 participants.
The verdict
NCT00768183, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The objective of this study was to compare the single-dose relative bioavailability of Alpharma Branded Products Division Inc. (KADIAN) 100 mg morphine sulfate extended-release capsules when dosed with alcohol under fasting and fed conditions compared to water.
Interventions
- DRUG KADIAN Capsule + alcohol (under fasting conditions)
- DRUG KADIAN Capsule + water (under fasting conditions)
- DRUG morphine sulfate IR oral solution + water
- DRUG KADIAN Capsule + alcohol (under fed conditions)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-05 |
| Est. Completion | 2006-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00768183
The ClinicalTrials.gov registry entry for NCT00768183 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which KADIAN Capsule + alcohol (under fasting conditions) is the first listed.
NCT00768183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00768183 about?
NCT00768183 is a clinical study titled "Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to Water". The objective of this study was to compare the single-dose relative bioavailability of Alpharma Branded Products Division Inc. (KADIAN) 100 mg morphine sulfate extended-release capsules when dosed with alcohol under fasting and fed conditions compared to water.
What is the current status of trial NCT00768183?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2006-05. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00768183?
The interventions under investigation include: KADIAN Capsule + alcohol (under fasting conditions) (DRUG), KADIAN Capsule + water (under fasting conditions) (DRUG), morphine sulfate IR oral solution + water (DRUG), KADIAN Capsule + alcohol (under fed conditions) (DRUG).
Who is sponsoring clinical trial NCT00768183?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.